The transplant outcomes of non-first-degree (NFD) related donors in haploidentical haematopoietic stem cell transplantation (haplo-HSCT) remain unclear. This multi-centre analysis compared NFD and first-degree (FD) related donors in haplo-HSCT using a low-dose anti-T-lymphocyte globulin/G-CSF-mobilised peripheral blood stem cell graft-based regimen. Ninety-nine patients (33 NFD; 66 FD) were included. All patients achieved myeloid and platelet engraftment. The 100-day cumulative incidence (CI) of aGVHD, 2-year CIs of relapse, cGVHD, and NRM, and 2-year probabilities of OS and GRFS were comparable between the two cohorts. In multivariate analysis, donor type (NFD vs. FD) had no impact on OS, PFS, GRFS, incidences of relapse, grade II-IV aGVHD or moderate-severe cGVHD. Older donor age was associated with a higher incidence of grade II-IV aGVHD (HR, 1.64, p = 0.03), moderate-severe cGVHD (HR, 1.92, p = 0.01) and worse GRFS (HR, 1.40, p = 0.02). A lower level of donor-recipient HLA matching was associated with a higher incidence of moderate-severe cGVHD (HR, 4.07, p = 0.02), and disease at complete remission was associated with better OS (HR, 0.21, p = 0.01) and PFS (HR, 0.3, p = 0.03). In conclusion, NFD donors may serve as feasible alternatives when FD donors are not available for haplo-HSCT.

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-021-01352-4DOI Listing

Publication Analysis

Top Keywords

moderate-severe cgvhd
12
first-degree donors
8
donors haploidentical
8
nfd donors
8
stem cell
8
donors haplo-hsct
8
grade ii-iv
8
ii-iv agvhd
8
associated higher
8
higher incidence
8

Similar Publications

Multiple factors have been described to influence the risk of acute or chronic graft-versus-host disease (aGVHD or cGVHD) after allogeneic hematopoietic cell transplantation (HCT), including underlying chronic myeloid leukemia (CML) and high-dose total body irradiation (TBI). However, the impact of the underlying disease or low-dose TBI on the risk of GVHD in the modern era has not been determined. The objective of this study was to determine risk factors for GVHD in the modern era in the setting of antithymocyte globulin (ATG)-based GVHD prophylaxis.

View Article and Find Full Text PDF

Introduction: The first-line treatment of moderate-severe chronic graft versus host disease (cGVHD) involves systemic corticosteroids ± calcineurin inhibitors. Around half of the patients will need second-line agents for corticosteroid-refractory/dependent (SR/SD) cGVHD. Herein, we report our experience using sirolimus as an add-on agent to corticosteroids in moderate-severe cGVHD.

View Article and Find Full Text PDF
Article Synopsis
  • REACH2 and REACH3 were clinical studies that compared ruxolitinib, a JAK1/JAK2 inhibitor, with the best available therapy in patients with steroid-refractory acute or chronic graft-versus-host disease (GVHD).
  • Early initiation of ruxolitinib treatment within 3 days of diagnosis significantly improved treatment outcomes, leading to longer response durations and higher complete response rates compared to starting treatment later.
  • Despite the occurrence of clinically relevant cytopenias (low blood cell counts), patients were able to manage these side effects and maintain effective doses of ruxolitinib, demonstrating its effectiveness over other treatments for managing GVHD.
View Article and Find Full Text PDF

A Pilot Study of UM171-Expanded Cord Blood Grafts for Tandem Auto/Allogeneic Hematopoietic Cell Transplant in High and Ultra-High-Risk Myeloma Patients.

Transplant Cell Ther

January 2025

Division of Hematology, Oncology and Transplantation, Department of Medicine, Maisonneuve-Rosemont Hospital, Montréal, Québec, Canada; Faculty of Medicine, Université de Montréal, Montréal, Québec, Canada.

Article Synopsis
  • Multiple myeloma (MM) poses significant treatment challenges, particularly for high-risk patients, with allogeneic hematopoietic cell transplantation (HCT) often resulting in severe side effects and high mortality rates.
  • This study investigates the safety and feasibility of using UM171-expanded cord blood transplantation combined with autologous HCT for patients with high-risk MM.
  • Out of 20 enrolled patients, 19 successfully underwent the UM171 procedure, highlighting potential improvements in patient outcomes despite the historical issues associated with cord blood transplantation.
View Article and Find Full Text PDF

Antibiotic Prophylaxis During Allogeneic Stem Cell transplantation-A Comprehensive Single Center Retrospective Analysis.

Transplant Cell Ther

December 2024

Department of Oncology, Hematology, Immuno-Oncology and Rheumatology, University Hospital Bonn, Bonn, Germany; Center for Integrated Oncology (CIO) ABCD, Aachen Bonn Cologne Düsseldorf, Germany. Electronic address:

Article Synopsis
  • A study was conducted to analyze the effects of omitting standard antibiotic prophylaxis during allogeneic hematopoietic stem cell transplantation (allo-HSCT), focusing on survival rates and the development of Graft-versus-Host disease (GvHD).
  • The research compared patient outcomes before and after the suspension of antibiotic prophylaxis, assessing factors such as severe infections, transplant-related mortality, and infections by multiresistant pathogens among 221 patients.
  • The results showed a trend towards better outcomes in the group without antibiotic prophylaxis; however, there were no significant differences found in overall survival or acute GvHD between the two groups.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!